Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Summary

Novo Nordisk is pursuing long-acting obesity drugs administered every one to three months, while Acadia Pharmaceuticals experienced a stock decline following Alzheimer's data. Nektar won a legal dispute with Eli Lilly and the FDA issued two approvals.